Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA): Insights into Pathogenesis, Diagnosis, and Management
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background: Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA) represents a unified conceptual framework proposed in 2011 to encompass diverse immune-mediated disorders triggered by adjuvant exposure in genetically predisposed individuals. Objective: This review aims to synthesize the current understanding of ASIA's pathogenesis, clinical manifestations, diagnostic approaches, and therapeutic strategies, while identifying critical gaps in existing research. Methods: A comprehensive narrative synthesis was conducted, examining literature from multiple databases (PubMed/MEDLINE, Scopus, Web of Science, Embase) for publications spanning from 2011 through 2025. Data were synthesized across four domains: immunopathogenic mechanisms, clinical phenotypes, evolution of diagnostic criteria, and emerging adjuvant substances. Results: The pathophysiology of ASIA syndrome is complex, involving innate immune activation, a breakdown of self-tolerance, and chronic inflammation. Primary triggers include aluminum-based vaccine adjuvants, silicone implants, and other biomaterials. Clinically, the syndrome manifests with significant heterogeneity, encompassing constitutional symptoms, musculoskeletal involvement, and multiorgan system pathology. Current diagnostic criteria require further refinement, and therapeutic management primarily emphasizes the removal of the inciting adjuvant and subsequent immunomodulation. Controversial aspects persist, including debates regarding its nosological validity, implications for vaccine safety, and medico-legal dimensions. Conclusion: Despite ongoing scientific debate, ASIA represents a valuable framework for understanding the link between adjuvant exposure and autoimmune phenomena. Future research must prioritize prospective cohort studies, advanced immunophenotyping, standardized diagnostic protocols, and the development of safer adjuvants to optimize patient care without compromising public health initiatives.
